Table 2.

Model parameters.

Parameters	Baseline	Range	Source
Probability
Incidence	0.238	0.1727–0.3333	6,48-50
Symptomatic infection	0.198	0.167–0.229	5
Seroprevalence of HEV antibody	0.0883	0.005–0.67	63,64
Probability of non-FHF	0.55	0.19–0.75	51-53
Probability of FHF	0.45	0.25–−0.81	51-53
Hospitalization rate	0.328	0.273–0.391	17,19
Death
Non-FHF
Pregnant woman	0	0.00–0.025	51-53,57, 58
Fetus#	0.05	0–0.10	51-53,57, 58
FHF
Pregnant woman	0.48	0.13–0.79	54-56
Fetus#	0.21	0.14–0.38	54-56
Efficacy of vaccine	0.933	0.721–1	17,19
Cost ($)
Vaccine (3 doses)	121.33	16.31–146.78	59,65-67
Administration (3 doses)	3.73	1.47-18	59, 60,68
Screening	4.08		59
Outpatient medical cost	134.24	74.98–219.29	59, 61
Inpatient medical cost
Non-FHF	2,169.10	510.46–6,771.39	59, 61
FHF	1,0581.68	1,025.25–2,7856.49	60
Medical cost of death
Non-FHF	5,000	2446.26–8,377.96	21, 24
FHF	13,600	12,000–24,932.46	22, 62
Fetus	2,956.68	2,446.26–5,000	21, 24
Work days lost
Outpatient	3.63	3–10	59, 60
Inpatient
Non-FHF	24	17.47–33.20	59, 69
FHF	30	17-40	54
Death	40	20–60	68
QALYs
Healthy/asymptomatic	1.00		60, 68
Outpatient	0.83		24, 60
Non-FHF	0.75		24, 60
Non-FHF (fetal death)	0.41		60
FHF	0.42		60, 70
FHF (fetal death)	0.21		60
Death	0		60, 68

Note. HEV: hepatitis E virus; FHF: fulminant hepatic failure; non-FHF: non fulminant hepatic failure; QALYs: quality-adjusted life years.

^#probability of fetal death with maternal survival.